TerminatedPhase 2NCT04727541

Neoadjuvant Bintrafusp Alfa in Patients With Resectable Biliary Tract Cancer

Studying Cholangiocarcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
AIO-Studien-gGmbH
Principal Investigator
Oliver Waidmann, Prof.Dr.
Johann Wolfgang Goethe University Hospital
Intervention
Bintrafusp alfa(drug)
Enrollment
3 target
Eligibility
18 years · All sexes
Timeline
20212022

Study locations (2)

Collaborators

Merck Serono GmbH, Germany

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04727541 on ClinicalTrials.gov

Other trials for Cholangiocarcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cholangiocarcinoma

← Back to all trials